DENVER, July 17, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will release its second quarter 2017 financial results on Tuesday, August 8, 2017 before the opening of U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | August 8, 2017 |
| Time | 9:00 a.m. EDT |
| Toll free (U.S.) | (888) 372-9592 |
| Webcast (live and replay) | www.bioscrip.com |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 51901836.
About BioScrip
BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts Stephen Deitsch Chief Financial Officer & Treasurer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 



